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Abstract
Follicular lymphoma (FL) is a B-cell non-Hodgkin lymphoma of germinal center (GC) origin with a distinctive tumor
microenvironment (TME) and a unique spectrum of mutations. Despite the important therapeutic advances, FL is still
incurable. During B-cell development, the GC reaction is a complex multistep process in which epigenetic regulators dynamically induce or suppress transcriptional programs. In FL, epigenetic gene mutations perturb the regulation of these programs, changing GC B-cell function and skewing differentiation towards tumor cells and altering
the microenvironment interactions. FL pathogenesis and malignant transformation are promoted by epigenetic
reprogramming of GC B cells that alters the immunological synapse and niche. Despite the extensive characterization of FL epigenetic signature and TME, the functional consequences of epigenetic dysregulation on TME and niche
plasticity need to be better characterized. In this review, first we describe the most frequent epigenomic alterations in
FL (KMT2D, CREBBP and EZH2) that affect the immunological niche, and their potential consequences on the informational transfer between tumor B cells and their microenvironment. Then, we discuss the latest progress to harness epigenetic targets for inhibiting the FL microenvironment. Finally, we highlight unexplored research areas and
outstanding questions that should be considered for a successful long-term treatment of FL.
Keywords: Hemato-oncology, Lymphoma, Immunotherapy, Epigenetic
Background
Follicular lymphoma (FL) is the most frequent indolent
B-cell non-Hodgkin lymphoma (yearly incidence: 2.7
cases per 1000,000 inhabitants in the USA in the 2014–
2018 period according to the National Cancer Institute
Surveillance, Epidemiology and End Results program).
It is characterized by abnormal B-cell clonal expansion
and originates from the germinal center (GC). Immunotherapy has drastically improved FL outcome. Specifically, the use of anti-CD20 monoclonal antibodies (such
as rituximab) has increased the patients’ overall survival
to 90%. However, many patients experience relapses and
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develop treatment resistance, or transformation to more
aggressive lymphoma types (usually diffuse large B cell
lymphoma (DLBCL) in 30% of patients) [1, 2]. Hence,
there is an urgent need of new clinical options for the
long-term cure of FL. Approximately 90% of patients
with FL harbor the t(14;18)(q32:q21) chromosomal translocation in which the immunoglobulin heavy chain (IGH)
enhancer region at 14q32 and the B-cell lymphoma 2
(BCL2) gene at 18q21 are juxtaposed. This translocation
is characterized by a transposition of the BCL2 oncogene
to the regulatory region of the IGH gene, thus leading
to BCL2 ectopic expression and constitutive activation
of the anti-apoptotic program. In patients with FL, this
translocation can be found also in bone marrow C
 D34+
+
CD19 B-cell precursors [3]. However, the detection of
BCL2 genetic aberrations at low frequency (40%) also in
healthy individuals is one of the many evidences supporting the hypothesis that this translocation is insufficient
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for FL development and that other genetic and epigenetic
alterations (such as BCL6) are required [4–6].
Epigenetic processes are implicated in the regulation of gene transcription and translation. They include
DNA methylation and histone modifications through
the transfer of acetyl or methyl groups. Deregulation of
such processes (e.g. aberrant DNA hypermethylation)
has been recognized as a central feature of hematologic
malignancies [7, 8], particularly FL where epigenome
alterations have been observed in almost all patients [9,
10]. This could be explained by the multistep GC reaction process in which gene expression is finely regulated by post-translational histone modifications and/or
chromatin remodeling. In FL, mutations in epigeneticrelated genes concern mainly histone methyltransferases
(KMT2D and EZH2) and histone acetyltransferases
(CREBBP and EP300), and they are mostly inactivating mutations, except in EZH2. They play a crucial role
in gene expression regulation by modifying lysine 4 on
histone 3 (H3K4) (KMT2D) and lysine 27 on histone 3
(H3K27) (EZH2, CREBBP and EP300) [9, 11]. Moreover,
these epigenome abnormalities are common in adult FL,
but not in the rare pediatric nodal FL that has a more
favorable prognosis [12]. The impact of these alterations
varies in function of the B-cell development stage. At
early stages, these mutations are sufficient to initiate lymphomagenesis, while at later stages, additional epigenetic
gene mutations might be required to support malignant
transformation [13].
At the cellular level, the multiple relapsing/remitting
cycles that characterize FL are partly due to the presence
of a common precursor cell (CPC) population enriched
in these early epigenetic driver and recurrent mutations,
particularly in histone modifiers. This “founder” population acts as a FL niche that sustains the tumor microenvironment (TME) reprogramming through molecular
(genetic and epigenetic) mechanisms to promote antitumor immune evasion and transformation [10].
In studies on FL, genetic/epigenetic alterations and
TME are often characterized separately; conversely, in
this review we wanted to discuss the impact of the FL
epigenome on TME functional plasticity to better understand this indolent cancer.

Page 2 of 7

The FL epigenome influences its microenvironment
Gene regulation by epigenetic mechanisms involves the
addition or removal of chemical groups on DNA or histones, catalyzed by enzymes called ‘writers’ and ‘erasers’.
Moreover, ‘readers’ are a distinct group of proteins that
are recruited to specific regions of the genome through
recognition of the epigenetic marks deposited or erased
by the ‘writers’ and ‘erasers’. Then, readers can modify/
adjust the chromatin state and regulate the expression
of target genes. DNA methylation and histone modifications are the most common epigenetic modifications.
The mechanisms through which epigenetic regulators
regulate gene expression have been described elsewhere
[14, 15], and will not be discussed in this review. Here,
we will focus on the mutations of the histone acetyltransferase CREBBP and the methyltransferases KMT2D and
EZH2 that play a key role in the FL microenvironment,
and have detrimental consequences on the anti-tumor
immune response.
FL is a cancer addicted to epigenetic gene mutations
that are detected in almost all patients (80%), and concern particularly the histone methyltransferases KMT2D
(90% of patients) and EZH2 (25%) and the histone acetyltransferases CREBBP (30–60%) and EP300 (9%). They are
frequently combined with other mutations, for instance
in linker and core histone genes and chromatin remodeling complexes [16]. All these mutations lead to a modification of the epigenetic landscape in FL that supports
tumor progression.
A specific feature of FL is its strong dependency on
its microenvironment. This is explained by various
mechanisms [17–19], but is essentially correlated to the
epigenetic changes that occur in the early stage of tumorigenesis. Indeed, the epigenetic dysregulation detected
in FL can affect the expression of genes that regulate
quantitatively and qualitatively the TME cell composition, thus influencing antigen presentation mechanisms,
immune signaling pathways, and cell recruitment to
escape immune surveillance and maintain an immunosuppressive microenvironment [19–21]. Therefore, these
epigenetic alterations substantially affect the patient outcomes by providing survival signals for cancer cells and
by hindering the anti-tumor immune response (Table 1).

Table 1 Summary of what is known about the FL epigenome
1) FL is addicted to epigenetic mutations, thus representing a good model of epi-cancer.
2) The most frequent epigenetic mutations in FL concerns genes that regulate the deposition of histone marks.
3) Most epigenetic mutations occur early in FL lymphomagenesis.
4) Mutations in the epigenetic regulators KMT2D, CREBBP and EZH2 affect the FL microenvironment.
5) Combination therapies targeting the FL epigenome and its immunological synapse represent promising future approaches for FL management.
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CREBBP mutations affect antigen presentation

In FL, the unbalance toward abnormal repression of
gene transcription might be explained by the loss of
histone 3 lysine 27 acetylation (H3K27ac; an active
transcription mark) catalyzed by CREBBP. CREBBP,
one of the most frequently mutated gene in FL (∼65%),
encodes a lysine acetyltransferase that activates gene
expression through acetylation of histone H3 lysine
18 (H3K18Ac), H3K27Ac, and other residues. Most
CREBBP mutations lead to single–amino acid changes
within the catalytic acetyltransferase domain that
reduce its acetyltransferase activity [22]. FL sequencing identified CREBBP mutations as early oncogenic
events, likely in the CPC founder population [23], thus
partly explaining their association with poor outcome
[24]. Interestingly, in FL, CREBBP mutations are correlated with reduced tumor expression of genes involved
in the MHC class II antigen presentation pathway, and
also with decreased B-cell receptor (BCR) and interferon signaling, accompanied by reduced proliferation
of tumor-infiltrating T cells [23, 25]. Overall, as the
lack of recognition and presentation of tumor antigens
by immune cells contributes to tumor invasion and
progression [25], these findings suggest that CREBBP
mutations directly promote lymphomagenesis by controlling the antigen presentation and interferon signaling pathways (Fig. 1). Interestingly, MHC pathway
deregulation is observed in the early stage of FL, and
also in transformed FL and DLBCL. FL progression to
a more aggressive form is associated with increased
somatic hypermutation activity, leading to accumulation of mutations on several downstream targets [26,
27]. All these studies indicate that MHC deregulation is
an important mechanism in FL pathogenesis and that it
occurs at every FL stage.
EZH2 and KMT2D mutations disrupt the immune synapse

EZH2 mutations were the first epigenetic alterations to be
reported in FL and to be investigated using murine models that showed their crucial role in early FL [28]. In FL,
the unbalance toward abnormal repression of gene transcription is characterized by an increase in the repressive trimethylation of lysine 27 on histone 3 (H3K27me3)
mark catalyzed by EZH2, the best characterized writer
in lymphoma. EZH2 is part of the polycomb repressor
2 complex, and is normally strongly expressed in GC B
cells. Indeed, EZH2 is one of the main regulators of the
GC phenotype by repressing the expression of regulators of B-cell differentiation (such as PRDM1 and IRF4)
through H3K27me3 deposition [28]. EZH2 mutations are
the third most important recurrent gene alterations in
FL, leading to increased H3K27me3 levels [29].
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Recently, Beguelin et al. showed that in Ezh2 conditional knock-in mice harboring the 
EZH2Y641F mutation in the catalytic domain that increases H3K27me3
levels, GC B cells accumulate in the light zone because
of the lack of the MYC-associated recycling signature,
thus impairing cell re-entry in the dark zone and promoting terminal differentiation. An important effect of
these Ezh2 mutations is the prevention of the induction
of genes (e.g. Cd69, Icosl, Icam1, Icam2, Slam, Ly108,
and Basp1) that are normally upregulated in GC centrocytes. This is associated with a preferential spreading of
the H3K27me3 mark from gene promoters to neighboring chromatin (due to their shared localization within
topologically associating domains) [9]. As these genes
are usually implicated in the formation of stable immune
synapses with T-follicular helper (TFH) cells, this impairment results in the loss of the crosstalk with these cells
and in the reduction of the CD40/CD40L response.
Importantly, GC B cells harboring Ezh2 mutations maintain GCs in the absence of CD40 signaling and TFH
interaction thanks to their increased crosstalk with follicular dendritic cells (FDCs). This is possible through aberrant overexpression of genes involved in the interaction
with FDCs, such as Tnfrsf13c (BAFF receptor), Ltb (FDC
precursor) [9, 30–32]. In line with these observations,
human FL with EZH2 mutations have an atypical denser
FDC network within follicles. Particularly, EZH2 mutant
GC B cells expand GCs until hyperplasia by enhancing
centrocyte survival and by evading TFH-directed clonal
selection and affinity maturation [9]. These studies suggest that EZH2 mutations lead to aberrant repression of
genes normally expressed during the GC reaction, thus
preventing the normal clonal selection of GC B-cells, and
allowing their survival and proliferation within the LZ
by depending only on survival signals from FDCs. This
reflects an epigenetic reprogramming that modifies the
GC B cell interactions with TFH cells and FDCs, thus
promoting malignant transformation and the establishment of the specific features of the FL immunological
synapse and niche (Fig. 1). As GC B cells are very T-cell
dependent, all these results might help to understand FL
resistance to T-cell-based therapies.
KMT2D encodes a SET domain-containing lysine
methyltransferase and catalyzes almost all mono-methylation of lysine 4 on histone 3 (H3K4me1). KMT2D is the
most recurrently mutated gene in FL, resulting in its loss
of function, thus promoting lymphomagenesis [33].
Transcriptomic analysis of a mouse model in which
Kmt2d was ablated showed an abnormal enrichment in
genes encoding immune-related proteins, such as CD40,
JAK-STAT, Toll-like receptor (TLR), IL-6, TNF, and BCR
signaling molecules. Among the KMT2D target genes,
there is also the TNFRSF14 (HVEM) tumor suppressor
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Fig. 1 Epigenetic dysregulation in FL modifies its microenvironment. Somatic mutations occur during the early steps of FL lymphomagenesis
(dashed circle, 1). Accumulation of genetic and epigenetic mutations promotes tumor progression. All these alterations accumulate during the
different phases of the GC reaction, contributing to the dysfunctional B-T cell crosstalk (dashed circle, 2) that favors tumor growth, escape, and
dissemination. 1- Schematic summary of the epigenetic regulators frequently mutated in FL: CREBBP, KMT2D and EZH2. These mutations occur
concurrently in most FL, but it is not known whether they act alone or cooperatively in driving B cell malignancy and in shaping the FL epigenome.
H3Kac, histone H3 lysine acetylation; H3K4me3, histone H3 lysine 4 trimethylation; H3K27me3, histone H3 lysine 27 trimethylation. Loss-of-function:
-, gain-of-function: + . 2- Consequences of epigenetic gene mutations on the immunological synapse. Impact of CREBBP, KMT2D and EZH2 gene
mutations in FL B cells on the crosstalk of tumor cells, T follicular helper (TFH) cells, and follicular dendritic cells (FDC). Alterations of this cross-talk
lead to inhibition of TFH immune synapse formation and antigen presentation, and increased FDC interactions. Specifically, CREBBP gene mutations
affect antigen presentation, and KMT2D and EZH2 gene mutations lead to a disrupted immune synapse. Red stars: decreased expression. Green
stars: increased expression. Dashed arrows: abnormal pathway

that is frequently mutated in FL (40% of patients) [13].
These mutations lead to the loss of the signaling cascade
induced by HVEM interaction with its inhibitory receptor BTLA. Disruption of the HVEM/BTLA crosstalk
causes hyperactivity of BCR signaling and consequently
infiltration of B
TLA+ TFH cells that produce high
amounts of TNF-α, IL-4, and lymphotoxin a1b2 (crucial
regulators of stroma differentiation and maintenance),
reflecting an enrichment in stromal TME [34].
Interestingly, Haebe et al. performed single-cell analysis of FL samples from two sites/patient and found that

in most patients, the two B-cell sub-clones grow separately with phenotypic divergences that correlate with
TFH cell infiltration through the CD40-CD40L crosstalk,
whereas the overall TME profile remains similar at both
sites [35]. This discrepancy might be explained by the
loss of the GC program flexibility and the ability to desynchronize and adopt different functional circuits, independently of the original clone [36]. These studies suggest
the existence of founder neoplastic clones with intrinsic
characteristics to modulate the TME in favor of disease
progression. Additionally, it has been reported that some
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gene alterations (e.g. cathepsin S, beta2 microglobulin, CIITA and RRAGC) [5, 27, 37–39] also support the
establishment of a biased immune synapse in FL, independently of epigenome modifications. However, this is
outside the scope of this review and will not be further
discussed.

Epigenetic modifying agents for FL treatment?
Due to FL indolence and slow progression, this malignancy is often diagnosed at an advanced stage with high
tumor burden. The classical chimeric anti-CD20 monoclonal antibody rituximab is an effective immunotherapy,
as single agent or in combination with first-line chemotherapy, to achieve long-term remission. Progression-free
survival is variable because of the non-responsiveness of
some patients [40].
Various agents are currently under investigation to
restore the anti-FL response and to reduce/inhibit its
supportive TME in order to improve the anti-tumor
immunity by reprogramming immune cells [41, 42]
(NCT02953509). Here, we discuss strategies to target
epigenetic alterations that might restore the immunological synapse in FL.
Because of the high rate of epigenetic dysregulation
in FL, epigenetic regulators represent targets of choice.
Ongoing clinical trials focus on CREBBP, EZH2, and
HVEM with promising responses in refractory/relapsed
FL. Although the most common loss-of-function KMT2D
and CREBBP mutations appear early in FL pathogenesis,
they are hard to target. However, as CREBBP and p300,
its closely related activator, regulate regulatory T cell
(Treg) differentiation, the inhibition of CREBBP/p300
loss-of function mutations in FL might have some effects
also on non-tumor cells within the TME [43].
As genes silenced upon CREBBP mutation are direct
targets of the BCL6/HDAC3 tumor-repressor complex,
the use of selective HDAC3 inhibitors (e.g. BRD3308)
allows reversing CREBBP loss-of-function effects by
restoring the immune response (T-cell anti-tumoral
function optimization by inducing antigen presentation
by MHC class II molecules, and interferon signaling) and
inhibiting lymphoma growth [44].
The EZH2 inhibitor tazemetostat is the only epigenetic
modifying agent approved by the US Food and Drug
Administration. An early clinical trial in non-Hodgkin
lymphoma (NCT01897571) showed its effectiveness,
but with no alternative treatment options for refractory
patients [45]. Although EZH2 inhibitors showed promising effects on the non-tumor microenvironment of other
cancers [46–48], their effects on the non-tumor microenvironment of FL has not been investigated yet. Importantly, as EZH2 mutations occur later in FL, they might
not be the best therapeutic target for long-term cure.
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Moreover, EZH2 is physiologically involved in the GC
reaction and in other important cellular mechanisms (e.g.
T and natural killer cell development), agents that target
mutated EZH2 in FL, rather than wild type EZH2, should
be developed. In addition, the specific targeting of EZH2
mutations is interesting to prevent the CPC population
rebound correlated with FL relapses and transformation.
Importantly, mutations in these different epigenetic
genes might interact and influence each other in FL. This
would imply the concomitant use of different epigenetic
modifying agents as a global epi-therapeutic strategy in
FL.
Therapeutic combinations are among the best options
to reduce the exceptional supporting role of the TME in
FL and to improve the anti-tumor response. This could
include the combination of epigenetic modifying agents
with immunotherapies or other anti-cancer drugs. For
instance, the response of HDAC3 inhibitors can be
enhanced by combining them with anti-PDL1 immune
checkpoint inhibitors to prevent interferon-induced
adaptive immune suppression [49]. Recently, two CD19directed CAR-T cell products (axicabtagene ciloleucel
and lisocabtagene maraleucel) have been approved for
B-cell lymphoma (DLBCL and FL at advanced stage),
including in combination with an anti-CD20 monoclonal
antibody and bendamustine, an alkylating agent [50–52].
All these preliminary results suggest that combination
therapies synergistically improve FL outcomes, and that
epigenetic modifying agents might be best used in association with other therapeutic agents (Table 1).
In conclusion, epigenetic modifying agents seems to be
a very promising avenue for FL therapy; however, i) their
complete response rate, as single agents, is still low; ii)
their effects too broad; and iii) their toxicity is high due
to their systemic delivery. This makes more difficult (as
it is also the case with other therapeutic agents) to treat
disease heterogeneity, non-responsiveness, and resistance to treatment [53]. High density lipoprotein (HDL)based natural biomaterials could be used to concentrate
their effects on the target and to minimize their toxicity,
by associating the benefits of therapeutic targeting and
controlled release of the active compound [54, 55].

Concluding remarks
Currently, FL management is based on immunotherapies and chemo/radiotherapies, thus undervaluing the
importance of epigenetic dysregulation and its strong
impact on the TME. FL is addicted to epigenetic modifications and strongly relies on its microenvironment,
suggesting a mutual impact and crucial role in FL pathogenesis. Understanding FL epigenetic landscape will
require detailed genetic, epigenetic and transcriptomic
approaches to determine how all these factors contribute
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Table 2 Outstanding questions
1) How do mutations in the epigenetic genes KMT2D, CREBBP and EZH2 (concomitantly or alone) orchestrate and promote the multi-scale (e.g.
genetic, molecular, cellular) alterations that drive lymphomagenesis and CPC establishment in FL?
2) What is the clonal evolution of CPC during FL course? How to properly define (in space and time) and target this population?
3) How does FL develop from aberrant GC reactions driven by EZH2 mutant-mediated reprogramming of the microenvironment?
4) How do the epigenetic regulator-TME bidirectional crosstalk interfere with the therapeutic response in FL?
5) Would it be possible to combine epigenetic modifiers that target tumor cells and non-tumor cells in the FL TME? If yes, what combination would
be the best for long-term efficacy and complete cure?

independently to FL development. Moreover, the functional characterization of FL epigenome would help to
dissect how the complex interplay of these alterations
contributes to modulate the TME and leads to immunosuppression, thus to FL pathogenesis. This will also
help to answer other outstanding questions (Table 2).
Importantly, the presence of many epigenetic alterations
in the CPC population increases the interest of epigenetic therapies for eradicating this founder clone in FL
and preventing transformation. Due to the flexibility and
reversibility of epigenetic modifications and the particular enrichment of epigenetic gene mutations in FL, they
are perfect therapeutic targets and accurate biomarkers for early diagnosis. However, the complexity of the
genetic/epigenetic alteration landscape within the same
tumor, as a result of the concerted epigenetic regulator
crosstalk, and the substantial impact of epigenetic drugs
also on the non-malignant microenvironment may make
it more difficult to predict the efficacy of epigenetic modifying agents in FL. Thus, for clinical translation, their
effects must be restricted to the targeted tumor population and their off-target effects strongly reduced by using
natural nanomaterials (such as HDL-based nanoparticles). Moreover, although epigenetic modifying agents
represent an interesting therapeutic option for FL, their
complete response rates, as single agents, have been low
[56, 57]. Hence, combination therapies targeting the epigenetic dysregulations (upstream), the immunological
synapse (downstream), and FL metabolic pathway would
help to better attack all the pro-tumor mechanisms of FL.
Lastly, the development of high throughput data analysis
and whole sequencing will allow addressing important
questions concerning the impact of FL epigenome on
its complex informational immunological synapse. Ultimately, a personalized therapy based on each patient’s
malignant epigenetic signature might be the best ways to
improve FL outcome.
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